Teza Capital Management LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 20,312 shares of the company's stock, valued at approximately $205,000.
Several other large investors also recently made changes to their positions in ROIV. Nuveen LLC acquired a new stake in shares of Roivant Sciences in the 1st quarter valued at about $31,988,000. Cutter Capital Management LP acquired a new stake in shares of Roivant Sciences in the 1st quarter valued at about $13,117,000. Vestal Point Capital LP acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at about $14,788,000. Troluce Capital Advisors LLC acquired a new stake in shares of Roivant Sciences in the 1st quarter valued at about $7,187,000. Finally, BlackBarn Capital Partners LP grew its stake in shares of Roivant Sciences by 15.2% in the 1st quarter. BlackBarn Capital Partners LP now owns 4,750,000 shares of the company's stock valued at $47,928,000 after buying an additional 625,000 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total value of $14,937,500.00. Following the transaction, the insider owned 36,089,108 shares in the company, valued at $451,113,850. The trade was a 3.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $11.72, for a total value of $1,172,000.00. Following the completion of the transaction, the chief executive officer owned 1,653,585 shares in the company, valued at $19,380,016.20. The trade was a 5.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,218,022 shares of company stock worth $39,010,006 in the last 90 days. Company insiders own 10.80% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on ROIV shares. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th. The Goldman Sachs Group upgraded Roivant Sciences to a "strong-buy" rating and set a $19.00 target price for the company in a research note on Thursday, July 10th. Finally, Citigroup began coverage on Roivant Sciences in a research note on Tuesday, September 2nd. They set a "buy" rating and a $16.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Strong Buy" and a consensus price target of $17.67.
Check Out Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Stock Down 0.8%
ROIV stock traded down $0.12 during mid-day trading on Monday, reaching $13.97. 836,871 shares of the company traded hands, compared to its average volume of 5,906,250. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $14.48. The firm's 50 day moving average price is $11.86 and its 200 day moving average price is $11.14. The stock has a market cap of $9.54 billion, a price-to-earnings ratio of -19.94 and a beta of 1.15.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
